Eisai Co. Ltd.’s Fycompa (perampanel) is only the second drug with a new mechanism of action approved for epilepsy in the last decade. Now the drug needs to find its place in clinical practice amid many treatment options, including generics.
FDA approved the once-daily AMPA-type glutamate antagonist as an add-on therapy for partial onset seizures with or without secondarily generalized...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?